EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oxford BioMedica's enterprise value is £334.74 Mil.
Oxford BioMedica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £89.54 Mil. Therefore, Oxford BioMedica's EV-to-Revenue for today is 3.74.
The historical rank and industry rank for Oxford BioMedica's EV-to-Revenue or its related term are showing as below:
LSE:OXB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.26 Med: 7.71 Max: 18.31
Current: 3.74
During the past 13 years, the highest EV-to-Revenue of Oxford BioMedica was 18.31. The lowest was 0.26. And the median was 7.71.
LSE:OXB's EV-to-Revenue is ranked better than 68.43% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs LSE:OXB: 3.74
As of today (2024-05-26), Oxford BioMedica's stock price is £3.27.
Oxford BioMedica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.93. Therefore, Oxford BioMedica's PS Ratio for today is 3.53.
Oxford BioMedica EV-to-Revenue Historical Data
The historical data trend for Oxford BioMedica's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oxford BioMedica's EV-to-Revenue
For the Biotechnology subindustry, Oxford BioMedica's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's EV-to-Revenue falls into.
Oxford BioMedica's current Enterprise Value is £334.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £89.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica's share price for today is £3.27.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.93.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Oxford BioMedica's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:OXB has been successfully added to your 